H.R. 1038 & S. 623, Access to Life-Saving Medicine Act; H.R. 1956, Patient Protection & Innovative Biologic Medicines Act; H.R. 5629, Pathway for Biosimilars Act; S. 316, Preserve Access to Affordable Generics Act; H.R. 1902, Protecting Consumer Access to Generic Drugs Act; Development of "Pedigree" or National Drug Trafficking System; H.R. 2900, Food & Drug Administration Amendments Act; H.R. 1980 & S. 1145, Patent Reform Act; FDA Globalization Act; Tax Incentives/Extensions (R&D Tax Credit)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Treasury - Dept of, Congressional Budget Office (CBO)
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Q2 Report
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...